IRUXOL MONO Collagenase Ointment 1.2U
IRUXOL MONO Ointment is an advanced enzyme-based product specifically formulated for the enzymatic debridement of necrotising wounds. Its primary active component, collagenase, is designed to act selectively on collagen, effectively freeing the wound bed of necrotic material. By targeting and breaking down native collagen, the ointment creates a cleaner wound environment, which is intended to support and speed up the natural wound healing process. The design philosophy of IRUXOL MONO centers on selective action, ensuring that dead tissue is addressed while preserving healthy surrounding tissue. With a history spanning over two decades of successful use across various chronic wound types, including leg ulcers, diabetic ulcers, and pressure sores, it serves as a reliable option for clinical wound management. The product is intended to provide healthcare professionals with a gentle and effective tool for preparing wound beds to improve overall patient outcomes.
Sizes & Specifications
- Specifications
- Available on request
Manufacturer: Smith & Nephew plc · Reference source: smith-nephew.com
Product Features
Design characteristics as published by Smith+Nephew.
Selective Debridement
The ointment acts selectively on collagen to remove necrotic tissue without harming healthy tissue.
Enzymatic Formulation
Contains collagenase and protease enzymes to break down and clear dead tissue from the wound bed.
Proven Efficacy
Supported by over 20 years of successful use in managing a variety of chronic wound types.
Documentation
Official IFU, technique guides and full specifications are available on request through Azmed Devices.
Product Identification & Specifications
Reference identifiers for procurement, registration and tender documentation.
| Manufacturer | Smith & Nephew plc |
|---|---|
| Brand | Smith+Nephew |
| Product Family | Advanced Wound Management |
| Country Availability | Azerbaijan |
Clinical Applications
The IRUXOL MONO Collagenase Ointment 1.2U is a enzymatic ointment for necrotising wound debridement in the Advanced Wound Management family from Smith & Nephew plc, used by interventional specialists in procedures where a enzymatic ointment for necrotising wound debridement of this class is indicated.
For the complete indications for use, contraindications and instructions for use (IFU), request the official Smith+Nephew documentation through our clinical team. Azmed Devices supplies the IRUXOL MONO Collagenase Ointment 1.2U to hospitals and clinics across Azerbaijan.
Downloads & Documentation
Instructions for use (IFU), technical datasheets and clinical literature for the IRUXOL MONO Collagenase Ointment 1.2U are available on request from our clinical team.
Request DocumentationFrequently Asked Questions
- What types of wounds can be treated with IRUXOL MONO Ointment?
- It can be used to remove dead tissue from wounds such as leg ulcers, diabetic ulcers, and pressure sores.
- Are there any products that should not be used with this ointment?
- It should not be used with products that interfere with the medicine, such as antiseptics, certain antibiotics like tetracyclines, heavy metals, detergents, and soaps.
- How can our hospital order IRUXOL MONO Collagenase Ointment 1.2U in Azerbaijan?
- Contact Azmed Devices at info@azmeddevices.com. We provide manufacturer documentation, registration status and tender support, and coordinate supply directly with Smith+Nephew.
